http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Hanna Joung ) (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
S-317 Influence of Additional Ballooning after Stent Implantation in Acute Myocardial Infarction.
( Hanna Joung ),( Ju Yeol Baek ),( Yong Mo Yang ),( Won Ik Lee ),( Seung-woon Rha ),( Byoung Geol Choi ),( Seung Won Jin ),( Byung Ryul Cho ),( Moo Hyun Kim ),( Doo-il Kim ),( Myung-ho Jeong ),( Sang 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Objective:?Most studies evaluating the benefit and risk of additional ballooning after stent implantation have involved patients with stable angina. However, it may be questionable in the context of patients presenting with acute myocardial infarction (AMI). We evaluated the clinical outcomes of additional ballooning after stent implantation in the patients who underwent AMI. Methods:?A total of 1618 AMI patients in the Korea TRI registry, a retrospective multicenter registry with 4890 patients who underwent percutaneous coronary intervention in 2009 at 12 centers were grouped according to performing additional ballooning (AB; N=814) and non-additional ballooning (Non-AB; N=804) after stent implantation. We compared TLR MACE at 12 month follow up, defined as total mortality, any myocardial infarction (MI), target vessel revascularization (TVR) between two groups.?Results:?After adjustment using 1:1 propensity score stratification, the incidence of TVR MACE at 12 month follow up was similar between both groups. However AB group had higher mortality (5.0% vs 2.4%; hazard ratio 2.15; 95% confidence interval 1.01 to 4.57; p=0.046) and the incidence of myocardial infarction (0.9% vs 1.6%; p=0.363) and TVR (3.8% vs 5.7%; p=0.195) were similar between two groups.?Conclusions: In patients with AMI, clinical result of AB after stent implantation could be similar with it of Non-AB in the 12month TVR MACE. However AB could be associated with significantly higher total mortality at 12 month follow up.
-
Yakuchinone 과 그 유도체의 합성 및 Nitric Oxide 생성 저해효능
윤정화(Joung Wha Yoon),안한나(Hanna Ahn),류재하(Jae-Ha Ryu),김희두(Hee-Doo Kim) 대한약학회 2001 약학회지 Vol.45 No.1
Novel yakuchinone derivatives have designed, synthesized and evaluated their inhibitory activity of NO production in lipopolysaccharide (LPS)-activated macrophages. From this study, some enone compounds have been found to be highly active in the assay. In view of the importance of NO in septic shock and inflammation, these compounds may be useful candidates for the development of new drug to treat endotoxemia and inflammation accmpanying overproduction of NO.
-
국소진행성 췌장암 환자에서 종격동 림프절 전이로 오인된 종격동 방선균증
허정원 ( Jung Won Heo ),정한나 ( Hanna Joung ),우인숙 ( In Sook Woo ),한치화 ( Chi Wha Han ),정윤화 ( Yun Hwa Jung ) 대한내과학회 2017 대한내과학회지 Vol.92 No.3
방선균증(actinomycosis)은 비특이적인 임상 양상과 종괴를 형성하는 특성으로 인해 흔히 종양과 혼동되는 경우가 많으며 특히 흉부형의 경우 폐암으로 오인된 예들이 다수 보고 되었다. 본 증례의 경우 췌장암 환자에서 폐 실질에는 병변이 없이 종격동의 림프절 비대 양상으로만 발현하여 종양의 림프절 전이를 동반한 진행과 구분이 어려웠고, 양전자 컴퓨터단층촬영에서도 <sup>18</sup>F-FDG의 국소적 섭취 증가를 보여 감별이 어려웠다. 이에 문헌고찰과 함께 보고하는 바이다. Actinomycosis is a rare chronic suppurative infectious disease caused by Actinomyces spp. Actinomyces are anaerobic Gram-positive bacteria that colonize the mouth, digestive tract, and genital tract. Thoracic actinomycosis is caused by the aspiration of oropharyngeal materials or the spread of cervicofacial infections. Therefore, poor oral hygiene, smoking, and immunodeficiency are risk factors. Actinomycoses are frequently misdiagnosed as anatomical malignancies and thus assessments of the diseases underlying malignancies are often complicated by the presence of actinomycoses. Here, we report a case of mediastinal actinomycosis presenting with clinical and radiological features of metastatic pancreatic cancer. Clinicians should consider the presence of actinomycosis when cancer patients fail to respond to anti-cancer treatments. (Korean J Med 2017;92:303-307)
-
Park, Jin‐,Hee,Lee, Kuy‐,Sook,Lim, Hyun‐,Joung,Kim, Hanna,Kwak, Hyun‐,Jeong,Park, Hyun‐,Young Wiley Subscription Services, Inc., A Wiley Company 2012 Journal of cellular biochemistry Vol.113 No.6
<P><B>Abstract</B></P><P>Peroxisome proliferator‐activated receptor (PPAR)δ is known to be expressed ubiquitously and involved in lipid and glucose metabolism. Recent studies have demonstrated that PPARδ is expressed in endothelial cells (ECs) and plays a potential role in endothelial survival and proliferation. Although PPARα and PPARγ are well recognized to play anti‐inflammatory, antiproliferative, and antiangiogenic roles in ECs, the general effect of PPARδ on angiogenesis in ECs remains unclear. Thus, we investigated the effect of the PPARδ ligand L‐165041 on vascular EC proliferation and angiogenesis in vitro as well as in vivo. Our data show that L‐165041 inhibited VEGF‐induced cell proliferation and migration in human umbilical vein ECs (HUVECs). L‐165041 also inhibited angiogenesis in the Matrigel plug assay and aortic ring assay. Flow cytometric analysis indicated that L‐165041 reduced the number of ECs in the S phase and the expression levels of cell cycle regulatory proteins such as cyclin A, cyclin E, CDK2, and CDK4; phosphorylation of the retinoblastoma protein was suppressed by pretreatment with L‐165041. We confirmed whether these antiangiogenic effects of L‐165041 were PPARδ‐dependent using GW501516 and PPARδ siRNA. GW501516 treatment did not inhibit VEGF‐induced angiogenesis, and transfection of PPARδ siRNA did not reverse this antiangiogenic effect of L‐165041, suggesting that the antiangiogenic effect of L‐165041 on ECs is PPARδ‐independent. Together, these data indicate that the PPARδ ligand L‐165041 inhibits VEGF‐stimulated angiogenesis by suppressing the cell cycle progression independently of PPARδ. This study highlights the therapeutic potential of L‐165041 in the treatment of many disorders related to pathological angiogenesis. J. Cell. Biochem. 113: 1947–1954, 2012. © 2012 Wiley Periodicals, Inc.</P>
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
